Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107,809,066
-
Total 13F shares
-
61,444,884
-
Share change
-
+3,183,943
-
Total reported value
-
$3,342,736,371
-
Put/Call ratio
-
518%
-
Price per share
-
$54.40
-
Number of holders
-
232
-
Value change
-
+$176,602,315
-
Number of buys
-
140
-
Number of sells
-
63
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q4 2020
As of 31 Dec 2020,
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) was held by
232 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
61,444,884 shares.
The largest 10 holders included
ARK Investment Management LLC, VANGUARD GROUP INC, Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., BlackRock Inc., STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, CHEVY CHASE TRUST HOLDINGS, INC., Atlas Venture Associates IX, LLC, and Atlas Venture Associates IX, LLC.
This page lists
234
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.